PortalPublikationenRetroperitoneoscopic adrenalectomy may be superior to laparo...

Retroperitoneoscopic adrenalectomy may be superior to laparoscopic transperitoneal adrenalectomy in terms of costs and profit: a retrospective pair-matched cohort analysis

Standard

Retroperitoneoscopic adrenalectomy may be superior to laparoscopic transperitoneal adrenalectomy in terms of costs and profit: a retrospective pair-matched cohort analysis. / Fischer, Andreas; Schöffski, Oliver; Nießen, Anna; Hamm, Alexander; Langan, Ewan A; Büchler, Markus W; Billmann, Franck.

in: SURG ENDOSC, Jahrgang 37, Nr. 10, 10.2023, S. 8104-8115.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Fischer, A, Schöffski, O, Nießen, A, Hamm, A, Langan, EA, Büchler, MW & Billmann, F 2023, 'Retroperitoneoscopic adrenalectomy may be superior to laparoscopic transperitoneal adrenalectomy in terms of costs and profit: a retrospective pair-matched cohort analysis', SURG ENDOSC, Jg. 37, Nr. 10, S. 8104-8115. https://doi.org/10.1007/s00464-023-10395-1

APA

Fischer, A., Schöffski, O., Nießen, A., Hamm, A., Langan, E. A., Büchler, M. W., & Billmann, F. (2023). Retroperitoneoscopic adrenalectomy may be superior to laparoscopic transperitoneal adrenalectomy in terms of costs and profit: a retrospective pair-matched cohort analysis. SURG ENDOSC, 37(10), 8104-8115. https://doi.org/10.1007/s00464-023-10395-1

Vancouver

Fischer A, Schöffski O, Nießen A, Hamm A, Langan EA, Büchler MW et al. Retroperitoneoscopic adrenalectomy may be superior to laparoscopic transperitoneal adrenalectomy in terms of costs and profit: a retrospective pair-matched cohort analysis. SURG ENDOSC. 2023 Okt;37(10):8104-8115. https://doi.org/10.1007/s00464-023-10395-1

Bibtex

@article{beb4491e0f0344a394643d9fdc6c8a5a,
title = "Retroperitoneoscopic adrenalectomy may be superior to laparoscopic transperitoneal adrenalectomy in terms of costs and profit: a retrospective pair-matched cohort analysis",
abstract = "BACKGROUND: A direct comparison of the cost-benefit analysis of retroperitoneoscopic adrenalectomy (RPA) versus the minimally invasive transperitoneal access (LTA) approach is currently lacking. We hypothesized that RPA is more cost effective than LTA; promising significant savings for the healthcare system in an era of ever more limited resources.METHODS: We performed a monocentric retrospective observational cohort study based on data from our Endocrine Surgery Registry. Patients who were operated upon between 2019 and 2022 were included. After pair-matching, both cohorts (RPA vs. LTA) were compared for perioperative variables and treatment costs (process cost calculation), revenue and profit.RESULTS: Two homogenous cohorts of 43 patients each (RPA vs. LTA) were identified following matching. Patient characteristics between the cohorts were comparable. In terms of both treatment-associated costs and profit, the RPA procedure was superior to LTA (costs: US$5789.99 for RPA vs. US$6617.75 for LTA, P = 0.043; profit: US$1235.59 for RPA vs. US$653.33 for LTA, P = 0.027). The duration of inpatient treatment and comorbidities significantly influenced the cost of treatment and the overall profit.CONCLUSIONS: RPA appears not only to offer benefits over LTA in terms of perioperative morbidity and length of hospital stay, but also has a superior financial cost/benefit profile.",
keywords = "Humans, Laparoscopy/methods, Adrenal Gland Neoplasms/surgery, Retrospective Studies, Adrenalectomy/methods, Length of Stay",
author = "Andreas Fischer and Oliver Sch{\"o}ffski and Anna Nie{\ss}en and Alexander Hamm and Langan, {Ewan A} and B{\"u}chler, {Markus W} and Franck Billmann",
note = "{\textcopyright} 2023. The Author(s).",
year = "2023",
month = oct,
doi = "10.1007/s00464-023-10395-1",
language = "English",
volume = "37",
pages = "8104--8115",
journal = "SURG ENDOSC",
issn = "0930-2794",
publisher = "Springer New York",
number = "10",

}

RIS

TY - JOUR

T1 - Retroperitoneoscopic adrenalectomy may be superior to laparoscopic transperitoneal adrenalectomy in terms of costs and profit: a retrospective pair-matched cohort analysis

AU - Fischer, Andreas

AU - Schöffski, Oliver

AU - Nießen, Anna

AU - Hamm, Alexander

AU - Langan, Ewan A

AU - Büchler, Markus W

AU - Billmann, Franck

N1 - © 2023. The Author(s).

PY - 2023/10

Y1 - 2023/10

N2 - BACKGROUND: A direct comparison of the cost-benefit analysis of retroperitoneoscopic adrenalectomy (RPA) versus the minimally invasive transperitoneal access (LTA) approach is currently lacking. We hypothesized that RPA is more cost effective than LTA; promising significant savings for the healthcare system in an era of ever more limited resources.METHODS: We performed a monocentric retrospective observational cohort study based on data from our Endocrine Surgery Registry. Patients who were operated upon between 2019 and 2022 were included. After pair-matching, both cohorts (RPA vs. LTA) were compared for perioperative variables and treatment costs (process cost calculation), revenue and profit.RESULTS: Two homogenous cohorts of 43 patients each (RPA vs. LTA) were identified following matching. Patient characteristics between the cohorts were comparable. In terms of both treatment-associated costs and profit, the RPA procedure was superior to LTA (costs: US$5789.99 for RPA vs. US$6617.75 for LTA, P = 0.043; profit: US$1235.59 for RPA vs. US$653.33 for LTA, P = 0.027). The duration of inpatient treatment and comorbidities significantly influenced the cost of treatment and the overall profit.CONCLUSIONS: RPA appears not only to offer benefits over LTA in terms of perioperative morbidity and length of hospital stay, but also has a superior financial cost/benefit profile.

AB - BACKGROUND: A direct comparison of the cost-benefit analysis of retroperitoneoscopic adrenalectomy (RPA) versus the minimally invasive transperitoneal access (LTA) approach is currently lacking. We hypothesized that RPA is more cost effective than LTA; promising significant savings for the healthcare system in an era of ever more limited resources.METHODS: We performed a monocentric retrospective observational cohort study based on data from our Endocrine Surgery Registry. Patients who were operated upon between 2019 and 2022 were included. After pair-matching, both cohorts (RPA vs. LTA) were compared for perioperative variables and treatment costs (process cost calculation), revenue and profit.RESULTS: Two homogenous cohorts of 43 patients each (RPA vs. LTA) were identified following matching. Patient characteristics between the cohorts were comparable. In terms of both treatment-associated costs and profit, the RPA procedure was superior to LTA (costs: US$5789.99 for RPA vs. US$6617.75 for LTA, P = 0.043; profit: US$1235.59 for RPA vs. US$653.33 for LTA, P = 0.027). The duration of inpatient treatment and comorbidities significantly influenced the cost of treatment and the overall profit.CONCLUSIONS: RPA appears not only to offer benefits over LTA in terms of perioperative morbidity and length of hospital stay, but also has a superior financial cost/benefit profile.

KW - Humans

KW - Laparoscopy/methods

KW - Adrenal Gland Neoplasms/surgery

KW - Retrospective Studies

KW - Adrenalectomy/methods

KW - Length of Stay

U2 - 10.1007/s00464-023-10395-1

DO - 10.1007/s00464-023-10395-1

M3 - SCORING: Journal article

C2 - 37658201

VL - 37

SP - 8104

EP - 8115

JO - SURG ENDOSC

JF - SURG ENDOSC

SN - 0930-2794

IS - 10

ER -